Description
Clinical trials show BACE1 inhibitors can reduce amyloid-β but fail to improve cognitive outcomes in AD patients. This mechanistic disconnect challenges the amyloid hypothesis and suggests unknown pathways linking Aβ reduction to cognitive preservation.
Gap type: contradiction Source paper: Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease. (2017, Expert opinion on investigational drugs, PMID:28817311)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:25.070591+00:00”, “resolution_summary”: “Resolved by hypothesis h-73124693: BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imbalance via PV Interneuron Hypofunction. Supporting evidence includes debate sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731.”, “match_counts”: {“hypothesis_matches”: 4, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-73124693”, “title”: “BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imbalance via PV Interneuron Hypofunction”, “score”: 0.227, “reason”: “20 token overlaps; entity overlap: bace1”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “target_gene”: “NRG1/ERBB4”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.743, “confidence_score”: 0.72, “status”: “promoted”, “pubmed_evidence_ids”: [“16990514”, “17099708”, “20393464”, “20943921”, “21209185”]}, {“id”: “h-a6e77292”, “title”: “SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via Autophagosome-Lysosome Fusion Dysfunction”, “score”: 0.227, “reason”: “20 token overlaps; entity overlap: bace1”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-083737-59771b32”, “target_gene”: “SGMS1, BECN1”, “target_pathway”: “Autophagy / beclin-1”, “disease”: “neurodegeneration”, “composite_score”: 0.734, “confidence_score”: 0.72, “status”: “promoted”, “pubmed_evidence_ids”: [“23827971”, “23977395”, “28028177”, “30243987”, “N/A”]}, {“id”: “h-796cfd1c”, “title”: “SMPD1 (Acid Sphingomyelinase) Inhibition for Ceramide Reduction and BACE1 Regulation”, “score”: 0.227, “reason”: “17 token overlaps; entity overlap: bace1”, “analysis_id”: “SDA-2026-04-15-gap-debate-20260410-112819-e40e0fa2”, “target_gene”: “SMPD1”, “target_pathway”: “Acid sphingomyelinase / ceramide signaling”, “disease”: “neurodegeneration”, “composite_score”: 0.732, “confidence_score”: 0.75, “status”: “promoted”, “pubmed_evidence_ids”: [“18547682”, “33897374”, “41191606”, “41249848”, “41428198”]}, {“id”: “hyp-SDA-2026-04-12-20260411-082446-2c1c9e2d-2”, “title”: “Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbates Amyloid Pathology”, “score”: 0.226, “reason”: “21 token overlaps; entity overlap: bace1”, “analysis_id”: “SDA-2026-04-12-20260411-082446-2c1c9e2d”, “target_gene”: “CHRNA7 (α7 nicotinic receptor), BACE1”, “target_pathway”: “Cholinergic signaling pathway”, “disease”: null, “composite_score”: 0.785, “confidence_score”: 0.55, “status”: “debated”, “pubmed_evidence_ids”: [“20600777”, “20943921”, “21921156”, “23201341”, “23324234”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.487, “reason”: “8 token overlaps; entity overlap: bace1, pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a_task_9aae8fc5”, “title”: “AD patients with TDP-43 pathology show worse cognitive impairment, but how TDP-43 mechanistically contributes to this severity is unknown. Understanding this could identify TDP-43 as a therapeutic target for cognitive preservation in AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.487, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062202-5c32c50a”, “quality_score”: 0.734, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-145418-c1527e7b”, “title”: “There’s a clear disconnect between improved mechanistic understanding of AD and therapeutic success, with continued phase 3 trial failures. This translation gap suggests fundamental flaws in target selection, trial design, or disease model assumptions that need resolution.\n\nGap type: contradiction\nSource paper: Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. (2019, Cell, PMID:31564456)”, “score”: 0.436, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-145418-c1527e7b”, “quality_score”: 0.5, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974_20260412-213444”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.412, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.7, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974_20260416-134419”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.412, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.65, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}